InvestorsObserver
×
News Home

Is Opko Health Inc. (OPK) a Good Choice in Diagnostics & Research Wednesday?

Wednesday, September 21, 2022 10:39 AM | InvestorsObserver Analysts

Mentioned in this article

Is Opko Health Inc. (OPK) a Good Choice in Diagnostics & Research Wednesday?

The 54 rating InvestorsObserver gives to Opko Health Inc. (OPK) stock puts it near the top of the Diagnostics & Research industry. In addition to scoring higher than 72 percent of stocks in the Diagnostics & Research industry, OPK’s 54 overall rating means the stock scores better than 54 percent of all stocks.

Overall Score - 54
OPK has an Overall Score of 54. Find out what this means to you and get the rest of the rankings on OPK!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 54 would rank higher than 54 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Opko Health Inc. Stock Today?

Opko Health Inc. (OPK) stock is trading at $1.99 as of 10:38 AM on Wednesday, Sep 21, an increase of $0.04, or 2.32% from the previous closing price of $1.94. The stock has traded between $1.92 and $2.00 so far today. Volume today is low. So far 267,419 shares have traded compared to average volume of 2,980,374 shares. Click Here to get the full Stock Report for Opko Health Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App